Lü SQ - Search Results

1

[Effects of proteasome inhibitors on leukemias].

Lü SQ, Yang JM, Wang JM. Lü SQ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):896-900. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007. PMID: 17708829 Review. Chinese.

2

[Expression of d-amino acid oxidase gene and green fluorescence protein gene transferred into k562e cells by retroviral vector containing internal ribosome entry site sequence].

Zhai YP, Wang JM, Zhang YS, Zhou H, Lu SQ. Zhai YP, et al. Among authors: lu sq. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002 Jun;10(3):209-11. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002. PMID: 12513787 Chinese.

3

[Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].

He Y, Yang JM, Wang JM, Zhou H, Lü SQ, Hu XX. He Y, et al. Among authors: lu sq. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):794-8. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. PMID: 18718063 Chinese.

4

[Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].

Lü SQ, Yang JM, Huang CM, Xu XQ, Zhou H, Song NX, Wang JM. Lü SQ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):869-73. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011. PMID: 21867604 Chinese.

5

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.

Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. Lü S, et al. J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. doi: 10.1124/jpet.108.138131. Epub 2008 May 23. J Pharmacol Exp Ther. 2008. PMID: 18502982

6

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.

Lü S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J. Lü S, et al. Exp Hematol. 2008 Oct;36(10):1278-84. doi: 10.1016/j.exphem.2008.04.013. Epub 2008 Jun 17. Exp Hematol. 2008. PMID: 18562081 Free article.

7

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.

Lü S, Wang J, Xu X, Ni X, Huang C, Qiu H, Hu X, Yang J. Lü S, et al. Int J Hematol. 2009 Jan;89(1):34-38. doi: 10.1007/s12185-008-0218-9. Epub 2008 Dec 13. Int J Hematol. 2009. PMID: 19082817 Clinical Trial.

8

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.

Lü S, Yang J, Chen Z, Gong S, Zhou H, Xu X, Wang J. Lü S, et al. Exp Hematol. 2009 Jul;37(7):831-7. doi: 10.1016/j.exphem.2009.04.001. Epub 2009 May 6. Exp Hematol. 2009. PMID: 19426847 Free article.

9

Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.

Huang C, Hu X, Wang L, Lü S, Cheng H, Song X, Wang J, Yang J. Huang C, et al. Cancer Chemother Pharmacol. 2012 Dec;70(6):801-9. doi: 10.1007/s00280-012-1953-4. Epub 2012 Sep 21. Cancer Chemother Pharmacol. 2012. PMID: 22996635

10

The resistance mechanisms of proteasome inhibitor bortezomib.

Lü S, Wang J. Lü S, et al. Biomark Res. 2013 Mar 1;1(1):13. doi: 10.1186/2050-7771-1-13. Biomark Res. 2013. PMID: 24252210 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters